Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.

Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. · 2004

Read Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. by Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc539292.txt.

Introduction

Donna M. Wilcock and six co-authors report a 2004 study in the Journal of Neuroinflammation on antibody treatment for Alzheimer's disease in old mice. The mice were bred to build up amyloid, the protein clumps tied to the disease. Most past work treated younger mice. Here the team gave weekly antibody shots to mice at ages near the end of a mouse life span, for up to five months.

Treatment fully reversed learning and memory loss in the oldest mice, and the gain held through the full course. Brain tissue clumps shrank sharply, showing that even old deposits can be cleared. Yet amyloid in blood vessel walls grew, and some spots showed tiny bleeds tied to longer treatment. The authors say human trials would need guards against that risk.

Catalog record

CREATORWilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D.
YEAR2004
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC539292

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage By Donna M Wilcock, Amyn Rojiani, Arnon Rosenthal, Sangeetha Subbarao, Melissa J Freeman, Marcia N Gordon, Dave Morgan Published in: Journal of Neuroinflammation DOI: 10.1186/1742-2094-1-24 ABSTRACT Abstract Background Anti-Aβ immunotherapy in transgenic mice reduces both diffuse and compact amyloid deposits, improves memory function and clears early-stage phospho-tau aggregates. As most Alzheimer disease cases occur well past midlife, the current study examined adoptive transfer of anti-Aβ antibodies to 19- and 23-month old APP-transgenic mice. Methods We investigated the effects of weekly anti-Aβ antibody treatment on radial-arm water-maze performance, parenchymal and vascular amyloid loads, and the presence of microhemorrhage in the brain. 19-month-old mice were treated for 1, 2 or 3 months while 23-month-old mice were treated for 5 months. Only the 23-month-old mice were subject to radial-arm water-maze testing. Results After 3 months of weekly injections, this passive immunization protocol completely reversed learning and memory deficits in these mice, a benefit that was undiminished after 5 months of treatment. Dramatic reductions of diffuse Aβ immunostaining and parenchymal Congophilic amyloid deposits were observed after five months, indicating that even well-established amyloid deposits are susceptible to immunotherapy. However, cerebral amyloid angiopathy increased substantially with immunotherapy, and some deposits were associated with microhemorrhage. Reanalysis of results collected from an earlier time-course study demonstrated that these increases in vascular deposits were dependent on the duration of immunotherapy. Conclusions The cognitive benefits of passive immunotherapy persist in spite of the presence of vascular amyloid and small hemorrhages. These data suggest that clinical trials evaluating such treatments will require precautions to minimize potential adverse events associated with microhemorrhage. BACKGROUND Alzheimer's disease is characterized not only by the presence of parenchymal amyloid deposits and intracellular tangles but also by the presence of amyloid deposits in the vasculature, a condition referred to as cerebral amyloid angiopathy (CAA). The CAA observed in both Alzheimer's disease patients [1] and some of the transgenic mouse models [2] is primarily composed of the shorter form of amyloid beta (Aβ), Aβ1–40, while the majority of amyloid deposits in the parenchyma are composed of Aβ1–42, although the compact amyloid deposits also contain Aβ1–40. Anti-Aβ immunotherapy has been considered as a potential treatment for Alzheimer's disease for some time [3,4]. Active immunization with a vaccine including Aβ1–42 fibrils progressed to human clinical trials where its administration was suspended due to meningoencephalitits in a subset of patients [5]. To date there have been pathology reports on two patients who participated in the trial and subsequently died [6,7]. Both reports note that while the numbers of parenchymal amyloid deposits appeared lower than expected in these cases, the CAA in these patients did not appear outside the normal range for Alzheimer's disease. In addition, one report mentioned multiple cortical hemorrhages and the presence of hemosiderin around the CAA vessels [7]. Given the adverse reactions to the active immunization, the irreversibility of such procedures and the variable antibody response to vaccines in older individuals [8], passive immunization against the Aβ peptide emerged as an alternative immunotherapeutic strategy. Studies in young and middle aged APP-transgenic mice have reported significant amyloid reductions with passive immunization [9-11]. Such treatments also demonstrate rapid improvements of memory function in APP-transgenic mice, sometimes without detectable reductions in amyloid [12-14]. Most recently, intracranial administration of anti-Aβ antibodies has been shown to not only remove Aβ but also clear, early-stage, hyperphosphorylated-tau aggregates [15]. Importantly, in the only prior study evaluating adoptive antibody transfer in older APP-transgenic mice, Pfeifer et al. [16] reported a doubling of cerebral microhemorrhages associated with significant reductions in amyloid burden after administration of an N-terminal specific anti-Aβ antibody. MATERIALS AND METHODS Experiment design Mice derived from APP Tg2576 mice were obtained from our breeding program at University of South Florida started in 1996 [17]. For the 5-month treatment study, 13 APP-transgenic mice, aged 23 months, were assigned to one of two groups. The first group received weekly intraperitoneal anti-Aβ antibody injections (antibody 2286; mouse-monoclonal anti-human Aβ28–40 IgG1; Rinat Neurosciences, Palo Alto, CA) for a period of 5 months (n = 6). The second group received weekly intraperitoneal anti-AMN antibody (2906; mouse-monoclonal anti-Drosophila amnesiac protein IgG1; Rinat Neurosciences, Palo Alto, CA) injections for a period of 5 months (n = 7). Seven nontransgenic mice were also assigned to one of two groups. The first group received weekly intraperitoneal anti-Aβ antibody injections for a period of 5 months (n = 4). The second group received weekly intraperitoneal anti-AMN antibody injections for a period of 5 months (n = 3). For the time course study of 1-, 2- or 3-month treatment, 22 APP-transgenic mice aged 19 months were assigned to one of four experimental groups, as described previously [14]. The first three groups received weekly intraperitoneal anti-Aβ antibody injections for 3 months, 2 months or 1 month, ending when all mice were 22 months of age. The fourth group received weekly intraperitoneal anti-AMN antibody injections for 3 months. Behavioral analysis Following 3 and 5 months of treatment, the mice from the 5-month study were subjected to a two-day radial-arm water-maze paradigm. The apparatus was a 6-arm maze as described previously [18]. On day one, 15 trials were run in three blocks of 5. A cohort of 4 mice were run sequentially for each block (i.e., each of 4 mice get trial one, then the same mice get trial two, etc.). After each 5-trial block, a second cohort of mice was run permitting an extended rest period before mice were exposed to the second block of 5 trials. The goal arm was different for each mouse in a cohort to minimize odor cues. The start arm was varied for each trial, with the goal arm remaining constant for a given individual for both days. For the first 11 trials, the platform was alternately visible then hidden (hidden for the last 4 trials). On day two, the mice were run in exactly the same manner as day one except that the platform was hidden forall trials. The number of errors (incorrect arm entries) was measured in a one-minute time frame. As standard practice, mice failing to make an arm choice in 20 seconds are assigned one error, but no mice in this study had to be assigned an error in this manner. The same individual administered the antibody treatments and placed mice in the radial-arm water maze. Due to the numbers of mice in the study the researcher was unaware of treatment group identity of each mouse. Also, the dependent measures in the radial-arm water-maze task are quantitative, not evaluative, so the potential for tester bias is reduced. In order to minimize the influence of individual trial variability, each mouse's errors for 3 consecutive trials were averaged producing 5 data points for each day, which were analyzed statistically by ANOVA using StatView (SAS Institute Inc., NC). Tissue preparation and histology On the day of sacrifice mice were weighed, overdosed with 100 mg/kg Nembutal (Abbott laboratories, North Chicago, IL), and then intracardially perfused with 25 mL of 0.9% sodium chloride. Brains were rapidly removed, and the left half of the brain was immersion fixed for 24

Read the complete text